Healthcare Industry News: Head and Neck Cancer
News Release - May 26, 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical MeetingsIncreased Survival, Durable Tumor Control and Biomarkers Predictive of High Response Rates to Be Reported at ASCO and ASGT
AUSTIN, Texas, May 26 (HSMN NewsFeed) -- Introgen Therapeutics, Inc. (Nasdaq: INGN ) will present data and update the results of clinical trials from ADVEXIN p53 therapy used in recurrent Head and Neck Cancer. The data will be concurrently presented at the annual meetings of the American Society of Gene Therapy and the American Society of Clinical Oncology. Additionally, the Company will present data from its Li-Fraumeni Cancer program in which ADVEXIN is used to successfully treat inherited cancer. Introgen recently announced it will provide ADVEXIN p53 therapy for compassionate use to treat qualified cancer patients suffering from Li- Fraumeni Syndrome. The American Society of Gene Therapy (ASGT) meeting is being held May 31 - June 4 in Baltimore, MD, and The American Society of Clinical Oncology (ASCO) meeting is being held June 2-6 in Atlanta, GA.
During presentations at the ASGT meeting and at an ASCO-sanctioned symposium, Introgen and its clinical collaborators will discuss clinical trial results and findings related to a set of prognostic indicators associated with high response rates and increased survival of ADVEXIN patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
Also to be presented are the results of a Phase 1 trial, conducted in Japan, of ADVEXIN in patients with advanced non-small cell cancer. In addition to ADVEXIN data, results from studies involving INGN 241 (mda-7/IL24 therapy) and INGN 007 viral cancer therapy programs will be presented.
ADVEXIN p53 therapy is a targeted molecular therapy with broad applicability in a wide range of tumor types and clinical settings because it targets one of the most fundamental and common molecular defects, abnormal p53 tumor suppressor function, associated with cancer initiation, progression and treatment resistance. Prognostic biomarkers can identify patients most likely to respond to ADVEXIN. ADVEXIN has been studied worldwide in a number of solid tumor types in multiple phase 1, 2 and 3 clinical trials.
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene- based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: http://www.introgen.com .
Source: Introgen Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.